GO:1905577 ganglioside GP1c binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:1905577 (ganglioside GP1c binding) is a molecular_function term defined as binding to ganglioside GP1c, a c-series polysialoganglioside.
• GP1c is synthesized in the Golgi by the same glycosyltransferase set that produces asialo-, a- and b-series gangliosides, linking c-series biosynthesis to core ganglioside metabolism.
• c-Series polysialogangliosides including GP1c are enriched in nervous tissue and are recognized by monoclonal antibodies such as Q211, M6704 and M7103.
• Developmental expression of c-series polysialogangliosides changes markedly in embryonic rat and chicken brain, indicating stage-specific roles.
• Synthetic ganglioside glycan libraries enable quantitative binding studies relevant to Siglec-7 and Siglec-9, providing chemical tools to probe GP1c-type recognition.
• Studying GP1c binding requires integrated glycobiology methods, including antibody-based detection, glycosyltransferase perturbation and CRISPR cell models.
Description
Ganglioside GP1c binding (GO:1905577) is a molecular_function term describing the selective non-covalent interaction of a protein or other biomolecule with ganglioside GP1c, a c-series polysialoganglioside. GP1c belongs to the c-series family of polysialogangliosides, which are characterized by their distinctive sialylation pattern and are detected in vertebrate nervous tissue by specific monoclonal antibodies such as Q211. The term captures a binding event rather than a catalytic activity, making it central to understanding how glycan-recognizing proteins decode c-series ganglioside signals on cell surfaces. GP1c is biosynthesized in the Golgi apparatus by the same set of glycosyltransferases that catalyze the formation of asialo-, a- and b-series gangliosides, indicating that c-series gangliosides are integrated into the core ganglioside biosynthetic machinery rather than being produced by a separate pathway. This shared enzymatic logic has practical implications: perturbations of common glycosyltransferases can alter GP1c levels and, consequently, GP1c-dependent binding events. For researchers, GO:1905577 matters because c-series polysialogangliosides such as GP1c show developmentally regulated expression in the nervous system of vertebrates, including embryonic rat and chicken brain. Antibody probes with different epitope specificities have been used to reveal these developmental changes, providing a foundation for mechanistic studies of GP1c recognition. In parallel, advances in modular synthesis of ganglioside glycans now allow controlled binding-affinity measurements against lectins such as Siglec-7 and Siglec-9, offering a route to dissect the molecular determinants of GP1c-type interactions.
ganglioside GP1c binding At A Glance
| GO ID | GO:1905577 |
|---|---|
| GO term | ganglioside GP1c binding |
| Ontology | molecular_function |
| Synonym | None listed |
| Major function | Selective non-covalent binding to ganglioside GP1c |
| Target ligand | Ganglioside GP1c (c-series polysialoganglioside) |
| Biosynthetic context | GP1c is formed in the Golgi by glycosyltransferases shared with asialo-, a- and b-series gangliosides |
| Tissue context | c-Series polysialogangliosides including GP1c are detected in vertebrate nervous tissue |
| Developmental relevance | Expression changes during embryonic brain development in rat and chicken |
| Detection tools | Monoclonal antibodies such as Q211, M6704 and M7103 |
What Is GO:1905577?
In the Gene Ontology, GO:1905577 (ganglioside GP1c binding) is defined as binding to ganglioside GP1c. It is a molecular_function term, meaning it describes the ability of a gene product to selectively interact with GP1c, a c-series polysialoganglioside, without implying catalysis or transport. GP1c itself is a member of the c-series polysialoganglioside family, which is synthesized in the Golgi by glycosyltransferases shared with asialo-, a- and b-series ganglioside biosynthesis. The term has no listed synonyms in QuickGO.
Why Is ganglioside GP1c binding Important in Cell Biology?
GO:1905577 is important because it defines the molecular recognition step by which proteins engage ganglioside GP1c, a c-series polysialoganglioside with developmentally regulated expression in the nervous system. Because GP1c is produced by the same Golgi glycosyltransferases that generate asialo-, a- and b-series gangliosides, changes in core ganglioside metabolism can directly influence GP1c availability and thus GP1c-binding events. Antibody-based studies have established that c-series polysialogangliosides are present in vertebrate nervous tissue and that their expression is temporally controlled during brain development. In addition, synthetic ganglioside glycan platforms now permit quantitative evaluation of binding affinities to lectins such as Siglec-7 and Siglec-9, supporting structure-function analysis of GP1c-type recognition.
• Defines a specific glycan-binding function for ganglioside GP1c, a c-series polysialoganglioside.
• Links c-series ganglioside biosynthesis to the core Golgi glycosyltransferase machinery shared with asialo-, a- and b-series gangliosides.
• Provides a framework for interpreting antibody-based detection of c-series polysialogangliosides in nervous tissue.
• Supports studies of developmental regulation of polysialogangliosides in embryonic brain.
• Enables structure-function dissection of ganglioside-protein interactions using synthetic glycan libraries.
• Relevant to neuroglycobiology and cell-surface recognition research.
• Helps interpret how glycosyltransferase perturbations alter c-series ganglioside profiles.
• Guides design of binding assays for lectins and antibodies with c-series specificity.
• Facilitates cross-species comparison of c-series polysialoganglioside expression.
• Supports annotation of gene products with glycan-binding activity in molecular_function ontologies.
Molecular Mechanism of ganglioside GP1c binding
Ligand identity and c-series context
In simple terms: GP1c is a specific sugar-lipid molecule on cells, and this term is about proteins sticking to it.
Ganglioside GP1c is a c-series polysialoganglioside, a member of a family of sialic-acid-rich glycosphingolipids detected in vertebrate nervous tissue by monoclonal antibodies such as Q211. The c-series classification reflects a distinct sialylation pattern relative to asialo-, a- and b-series gangliosides, and GP1c is formed in rat liver Golgi by the same set of glycosyltransferases that catalyze asialo-, a- and b-series biosynthesis. Thus, the ligand for GO:1905577 is not an isolated exotic glycan but a product of shared core ganglioside enzymatic machinery.
Biosynthetic origin of GP1c
In simple terms: GP1c is built in the Golgi by enzymes that also make other gangliosides.
Biochemical studies in rat liver Golgi demonstrated that the c-series gangliosides GT3, GT2 and GP1c are formed by the same set of glycosyltransferases that catalyse the biosynthesis of asialo-, a- and b-series gangliosides. This shared enzymatic origin means that the availability of GP1c for binding interactions is coupled to the general flux of ganglioside biosynthesis. Consequently, experimental manipulation of common glycosyltransferases can be expected to alter GP1c levels and downstream GP1c-binding events.
Developmental regulation of c-series gangliosides
In simple terms: The amount of these c-series gangliosides changes as the brain develops.
Developmental studies using monoclonal antibodies M6704 and M7103 revealed changes in C-series polysialogangliosides in chick brains, with different epitope specificities distinguishing related glycan structures. In embryonic rat and chicken brain, a polysialoganglioside antigen reacting with monoclonal antibody Q211 showed developmentally regulated expression. These findings indicate that the ligand for GO:1905577 is under temporal control during neurodevelopment, which is relevant when interpreting binding data across developmental stages.
Antibody and lectin recognition of GP1c-type glycans
In simple terms: Antibodies and lectins can be used as tools to detect and study GP1c binding.
Monoclonal antibodies such as Q211, M6704 and M7103 have been used to detect c-series polysialogangliosides in nervous tissue, providing epitope-specific probes for GP1c-related structures. More recently, comprehensive modular synthesis of ganglioside glycans enabled evaluation of binding affinities to Siglec-7 and Siglec-9, illustrating how defined glycan libraries can be used to quantify recognition of ganglioside structures. Such tools support mechanistic dissection of GO:1905577 by allowing controlled comparison of binding across related ganglioside ligands.
Experimental perturbation of GP1c availability
In simple terms: Changing the enzymes that make gangliosides changes how much GP1c is available to bind.
Because GP1c is produced by glycosyltransferases shared with other ganglioside series, perturbations of these enzymes in Golgi-based systems can alter c-series ganglioside formation. Researchers can therefore use glycosyltransferase manipulation, together with antibody-based detection, to test how changes in GP1c levels affect binding events annotated to GO:1905577. Combining such perturbations with synthetic glycan binding assays provides a route to separate ligand-availability effects from intrinsic binding-affinity effects.
Key Genes Involved in GO:1905577 ganglioside GP1c binding
The following genes and gene products are relevant to ganglioside GP1c binding (GO:1905577), based on the verified literature covering c-series ganglioside biosynthesis, antibody detection and glycan-binding assays.
| Gene | Major Role | Research Relevance |
|---|---|---|
| Glycosyltransferase set (asialo-, a-, b- and c-series) | Catalyzes formation of GT3, GT2 and GP1c in rat liver Golgi | Core enzymes whose perturbation alters GP1c availability for binding studies |
| Q211 antibody target antigen | Polysialoganglioside antigen in vertebrate nervous tissue | Detects c-series polysialogangliosides including GP1c-related structures |
| M6704 antibody target antigen | C-series polysialoganglioside epitope in chick brain | Reveals developmental changes in c-series gangliosides |
| M7103 antibody target antigen | C-series polysialoganglioside epitope with distinct specificity | Distinguishes related c-series glycan structures |
| Q211-reactive antigen (embryonic rat/chicken) | Developmentally regulated polysialoganglioside | Links GP1c-type expression to neurodevelopment |
| Siglec-7 | Ganglioside glycan-binding lectin evaluated with synthetic glycans | Model lectin for quantitative binding-affinity studies |
| Siglec-9 | Ganglioside glycan-binding lectin evaluated with synthetic glycans | Model lectin for quantitative binding-affinity studies |
| GT3 biosynthetic enzymes | Produce c-series ganglioside GT3 in Golgi | Upstream of GP1c in c-series pathway |
| GT2 biosynthetic enzymes | Produce c-series ganglioside GT2 in Golgi | Intermediate in c-series pathway leading to GP1c |
| GP1c biosynthetic enzymes | Produce GP1c in rat liver Golgi | Directly determine ligand availability for GO:1905577 |
| Asialo-series glycosyltransferases | Shared enzymes for asialo-series gangliosides | Demonstrate pathway overlap with c-series |
| a-Series glycosyltransferases | Shared enzymes for a-series gangliosides | Demonstrate pathway overlap with c-series |
| b-Series glycosyltransferases | Shared enzymes for b-series gangliosides | Demonstrate pathway overlap with c-series |
| Golgi glycosylation machinery | Site of GP1c biosynthesis | Experimental compartment for perturbation studies |
| Monoclonal antibody probes (Q211, M6704, M7103) | Detect c-series polysialogangliosides | Essential reagents for expression and localization studies |
| Synthetic ganglioside glycan library components | Defined glycans for binding assays | Enable controlled affinity measurements |
How Is ganglioside GP1c binding Regulated?
Regulation of ganglioside GP1c binding (GO:1905577) is primarily governed by the availability of the GP1c ligand, which depends on the activity of Golgi glycosyltransferases shared with asialo-, a- and b-series ganglioside biosynthesis. Developmental studies show that c-series polysialoganglioside expression is temporally regulated in embryonic brain, indicating that ligand presentation changes with developmental stage. Antibody-based detection with Q211, M6704 and M7103 provides tools to monitor these changes and to assess how regulation of glycosylation affects GP1c-dependent binding events. Synthetic glycan binding assays further allow evaluation of how structural features of ganglioside glycans influence recognition by lectins such as Siglec-7 and Siglec-9.
ganglioside GP1c binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| Shared Golgi glycosyltransferases | Altered ganglioside biosynthesis affecting c-series GP1c availability | Knockout of glycosyltransferase genes in Golgi-competent cell lines |
| Q211-reactive antigen | Developmental nervous tissue expression changes | Embryonic rat and chicken brain tissue models |
| M6704/M7103 epitopes | C-series polysialoganglioside developmental regulation | Chick brain developmental series |
| Siglec-7 | Ganglioside glycan recognition | Synthetic glycan binding assays |
| Siglec-9 | Ganglioside glycan recognition | Synthetic glycan binding assays |
Neurodevelopmental and neurological contexts
c-Series polysialogangliosides including GP1c are expressed in vertebrate nervous tissue and show developmentally regulated expression in embryonic rat and chicken brain. Because GO:1905577 describes binding to GP1c, alterations in c-series ganglioside presentation during development could affect protein-glycan recognition events in the nervous system. Antibody probes such as Q211, M6704 and M7103 enable monitoring of these glycan changes in developmental and neurological research models.
Glycosylation pathway disorders
GP1c is synthesized by the same Golgi glycosyltransferases that produce asialo-, a- and b-series gangliosides, so perturbations in core ganglioside biosynthesis could influence c-series ganglioside levels. Such perturbations may alter the ligand available for GO:1905577-annotated binding events, providing a mechanistic link between glycosylation pathway dysfunction and glycan-binding phenotypes. Experimental systems that manipulate these shared enzymes are therefore useful for probing disease-relevant changes in GP1c-dependent recognition.
Glycan-lectin recognition in disease research
Synthetic ganglioside glycan libraries have been used to evaluate binding affinities to Siglec-7 and Siglec-9, which are lectins relevant to immune and glycan-recognition research. These platforms provide a way to study how structural features of ganglioside glycans, including c-series structures such as GP1c, influence protein binding. Such approaches complement antibody-based detection of c-series polysialogangliosides in tissue.
From ganglioside GP1c binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of a shared glycosyltransferase reduce GP1c levels? | Knockout cell model of the glycosyltransferase |
| Does a point mutation in a glycan-binding protein alter GP1c recognition? | Point-mutation knock-in cell model |
| Can a tagged binding protein be used to localize GP1c interactions? | Tagged knock-in of the binding protein |
| Does overexpression of a lectin increase GP1c-dependent binding signal? | Overexpression cell model |
| How does developmental stage affect c-series ganglioside expression? | Embryonic rat and chicken brain tissue series |
| Can synthetic glycans compete for GP1c-binding proteins? | In vitro binding assay with synthetic ganglioside glycans |
How to Study the ganglioside GP1c binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Monoclonal antibody detection (Q211) | Presence of c-series polysialogangliosides in tissue | Nervous tissue expression studies |
| Monoclonal antibody detection (M6704/M7103) | C-series polysialoganglioside epitopes with different specificities | Developmental chick brain studies |
| Embryonic brain profiling | Developmental changes in polysialoganglioside antigen | Rat and chicken embryonic brain series |
| Golgi glycosyltransferase assay | Formation of GT3, GT2 and GP1c | Rat liver Golgi biochemical studies |
| Synthetic glycan binding assay | Binding affinity to Siglec-7 and Siglec-9 | Structure-function analysis of ganglioside glycans |
| Epitope specificity comparison | Distinguishes related c-series structures | Antibody characterization |
| Cross-species comparison | Conservation of c-series expression patterns | Vertebrate neurodevelopment research |
Antibody-based detection of c-series gangliosides
Monoclonal antibodies such as Q211, M6704 and M7103 have been used to detect c-series polysialogangliosides in nervous tissue and to reveal developmental changes in expression. These reagents allow researchers to monitor the GP1c-related ligand pool that underlies GO:1905577 binding events. Epitope-specific antibodies with different specificities help distinguish closely related c-series structures.
Glycosyltransferase perturbation in Golgi systems
Because GP1c is formed in rat liver Golgi by the same glycosyltransferases that produce asialo-, a- and b-series gangliosides, biochemical perturbation of these enzymes provides a direct way to alter c-series ganglioside formation. Such experiments can be combined with antibody detection to assess how changes in enzyme activity affect GP1c availability. This approach is useful for linking biosynthetic flux to binding outcomes.
Synthetic glycan binding assays
Comprehensive modular synthesis of ganglioside glycans has enabled evaluation of binding affinities to Siglec-7 and Siglec-9. These assays provide quantitative readouts of glycan-protein recognition and can be adapted to test c-series structures such as GP1c. They complement tissue-based antibody studies by isolating the contribution of glycan structure to binding.
Developmental expression profiling
Developmental studies in chick, rat and chicken brain have documented changes in c-series polysialoganglioside expression using monoclonal antibody probes. Profiling across developmental stages helps determine when GP1c is available for binding and how this correlates with biological processes. Such data are essential for interpreting GO:1905577 in a physiological context.
How CRISPR Can Be Used to Study GO:1905577 ganglioside GP1c binding
Knockout
CRISPR knockout of glycosyltransferases shared with asialo-, a- and b-series biosynthesis can be used to reduce GP1c formation in cells, since GP1c is produced by the same enzyme set in Golgi. Such knockouts allow researchers to test whether loss of GP1c ligand availability affects binding events annotated to GO:1905577. Antibody-based detection with Q211 and related probes can confirm changes in c-series ganglioside levels.
Point Mutation
Point mutations can be introduced into candidate glycan-binding proteins to test which residues are required for GP1c recognition. Synthetic ganglioside glycan binding assays provide a quantitative readout for comparing wild-type and mutant proteins. This approach helps define the structural determinants of GO:1905577 binding specificity.
Knock-in
Knock-in of tagged binding proteins enables localization and interaction studies of GP1c-binding factors in cells. Tagged knock-ins can be combined with antibody-based detection of c-series polysialogangliosides to correlate protein localization with ligand distribution. Such models support mechanistic studies of GO:1905577 in a physiological context.
Overexpression
Overexpression of candidate lectins or binding proteins can amplify GP1c-dependent binding signals for detection. This is particularly useful when combined with synthetic glycan binding assays that measure affinity to ganglioside structures. Overexpression models also allow comparison of binding specificity across related ganglioside ligands.
How EDITGENE Supports ganglioside GP1c binding Research
Researchers studying ganglioside GP1c binding-related genes often need to determine whether a candidate gene is causally involved in GP1c recognition, how glycosyltransferase perturbations alter ligand availability, and which protein domains mediate binding. EDITGENE provides CRISPR-based cell models and screening services designed to answer these questions with reproducible, publication-ready data.
Contact EDITGENE today to design your custom CRISPR model for ganglioside GP1c binding research.
Frequently Asked Questions About ganglioside GP1c binding
What is ganglioside GP1c binding?
Ganglioside GP1c binding (GO:1905577) is a molecular_function term defined as binding to ganglioside GP1c, a c-series polysialoganglioside.
What is GO:1905577?
GO:1905577 is the Gene Ontology identifier for ganglioside GP1c binding, a molecular_function term.
What is ganglioside GP1c?
GP1c is a c-series polysialoganglioside formed in rat liver Golgi by the same glycosyltransferases that produce asialo-, a- and b-series gangliosides.
What genes are involved in ganglioside GP1c binding?
Genes encoding the shared Golgi glycosyltransferases that produce GT3, GT2 and GP1c are directly relevant, along with lectins such as Siglec-7 and Siglec-9 used in glycan binding assays.
How is GP1c synthesized?
GP1c is formed in the Golgi by the same set of glycosyltransferases that catalyse asialo-, a- and b-series ganglioside biosynthesis.
Which antibodies detect c-series polysialogangliosides?
Monoclonal antibodies Q211, M6704 and M7103 have been used to detect c-series polysialogangliosides in nervous tissue.
Is GP1c expression developmentally regulated?
Yes, developmental studies in chick, rat and chicken brain show changes in c-series polysialoganglioside expression.
How can I study ganglioside GP1c binding in the lab?
Approaches include antibody-based detection, glycosyltransferase perturbation in Golgi systems, and synthetic glycan binding assays.
What cell models are useful for GP1c binding research?
Knockout, point-mutation, knock-in and overexpression cell models targeting glycosyltransferases or candidate binding proteins are suitable.
Why is GO:1905577 important for neurobiology?
c-Series polysialogangliosides including GP1c are expressed in vertebrate nervous tissue and show developmental regulation, making GP1c binding relevant to neurodevelopmental research.
Conclusion
GO:1905577 (ganglioside GP1c binding) defines a specific molecular recognition event involving a c-series polysialoganglioside that is synthesized by the same Golgi glycosyltransferases as asialo-, a- and b-series gangliosides. Antibody-based studies have established that c-series polysialogangliosides are present in vertebrate nervous tissue and are developmentally regulated, providing a physiological context for GP1c-binding research. Synthetic glycan binding assays further enable quantitative analysis of ganglioside recognition by lectins such as Siglec-7 and Siglec-9. Together, these tools support mechanistic and disease-relevant studies of GP1c-dependent binding.
References
- 1. Adak AK et al.. 2025. Comprehensive Modular Synthesis of Ganglioside Glycans and Evaluation of their Binding Affinities to Siglec-7 and Siglec-9.. Adv Sci (Weinh) 12(2):e2412815 PMID: 39555730
- 2. Greis C et al.. 1990. c-pathway polysialogangliosides in the nervous tissue of vertebrates, reacting with the monoclonal antibody Q211.. Brain Res 517(1-2):105-10 PMID: 1695858
- 3. Hirabayashi Y et al.. 1988. Developmental changes of C-series polysialogangliosides in chick brains revealed by mouse monoclonal antibodies M6704 and M7103 with different epitope specificities.. J Biochem 104(6):973-9 PMID: 2468656
- 4. Rösner H et al.. 1988. Developmental expression in embryonic rat and chicken brain of a polysialoganglioside-antigen reacting with the monoclonal antibody Q 211.. Brain Res 470(2):161-71 PMID: 3064875
- 5. Iber H et al.. 1992. The c-series gangliosides GT3, GT2 and GP1c are formed in rat liver Golgi by the same set of glycosyltransferases that catalyse the biosynthesis of asialo-, a- and b-series gangliosides.. Glycobiology 2(2):137-42 PMID: 1606358
